Skip to main content
. Author manuscript; available in PMC: 2011 Jun 1.
Published in final edited form as: Gene Ther. 2010 Jul 22;17(12):1430–1441. doi: 10.1038/gt.2010.100

Figure 5. HIF-Ad and HIF-Ad-IL4 have anti-tumor activity which is superior to the HYPR-Ads.

Figure 5

LN229 tumor xenografts were established subcutaneously in nu/nu mice (Day 1). (a) Tumors (average size of 92 mm3) were intratumorally injected with 2×108 IFU of HIF-Ad-IL4, Ad5WT or PBS on Days 26 and 29. n=10 mice/group. (b) Tumors (average size of 235 mm3) were intratumorally injected with 2×108 IFU of HIF-Ad, HIF-Ad-IL4, Ad5WT or PBS on Days 28 and 34. n=4 mice/group. (c) Tumors (average size of 110 mm3) were intratumorally injected with 5 × 107 IFU of HIF-Ad (n=9), HYPR-Ad#1 (n=9), or PBS (n=8) on Days 35 and 39. (d) Tumors (average size of 226 mm3) were intratumorally injected with 1×106 IFU of HIF-Ad-IL4 (n=8), HYPR-Ad-IL4 (n=9), or PBS (n=8) on Days 45 and 49. Tumor growth was monitored by caliper measurement. The data represent the mean ± SEM.